

# Wound Care Intelligence Report

Wound Care · Skin Substitutes · Diabetic Foot Ulcers

● LIVE INGEST

Last refresh — 07 May 2026 21:28:48Z

Window — last 90 days

Pipeline — tools/scout-ingest

<p>TRACKED SIGNALS</p> <p><b>1,596</b></p> <p>Public, source-cited</p>	<p>SOURCES ACTIVE</p> <p><b>4 / 6</b></p> <p>Of 6 wired</p>	<p>COMPANIES MONITORED</p> <p><b>30</b></p> <p>Atlas-linked dossiers</p>	<p>CRITICAL / HIGH</p> <p><b>114</b></p> <p>Material signals (90d)</p>
--	---	--	--

RISK REGISTER · THE COST OF SEEING LATE Adversarial verification scope

## Three exposures every wound-care portfolio carries today.

---

**Reimbursement Cliff Risk**

Active CMS LCD signals tracked across the 2025–2026 cellular and tissue-based product rewrite cycle. A single coverage decision can erase 9-figure run-rate revenue without warning.

**CALIBRATING · NEXT REFRESH**

---

**Adverse Event Lag**

PubMed signals indexed in the 90-day window. The lag between first published case report and FDA action is where funds reading the literature first reprice first.

**1,000**








---

**Pre-Mortem Coverage**

Wound-care companies under continuous SCOUT monitoring across SEC, ClinicalTrials.gov, PubMed, and CMS LCD. No diligence gap closes without source-cited verification.

**30 / 30**

## What we are watching

FDA openFDA		333
ClinicalTrials.gov		163
PubMed		1000
SEC EDGAR		100
CMS LCD		0
USPTO Patents		0
Manufacturer Pipelines		0

## Top 10 by severity and recency

<p><b>PUBMED</b> <b>CRITICAL</b> 2026-04-29</p> <p><b>Self-Cascading Copper-Based Nanoassemblies Trigger Bacterial Cuproptosis-Like Death and Promote Wound Healing for Diabetic Drug-Resistant Bacterial Infections.</b></p> <p>Feng T</p> <p>Self-Cascading Copper-Based Nanoassemblies Trigger Bacterial Cuproptosis-Like Death and Promote Wound...</p> <p><a href="#">PubMed (NCBI E-utilities) ↗</a></p>	<p><b>PUBMED</b> <b>CRITICAL</b> 2026-04-15</p> <p><b>Targeting programmed cell death pathways in diabetic foot ulcers: Mechanisms and therapeutic strategies.</b></p> <p>Liang C</p> <p>Targeting programmed cell death pathways in diabetic foot ulcers: Mechanisms and therapeutic strategies.</p> <p><a href="#">PubMed (NCBI E-utilities) ↗</a></p>
<p><b>FDA</b> <b>CRITICAL</b> 2016-08-17</p> <p><b>HeartWare Ventricular Assist System (HVAD), US product: Model No.: H103; and International Product: Model No.: H104XX. Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. Designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter.</b></p> <p>HeartWare, Inc</p> <p>Foreign material found within the driveline connector of the HVAD Pump that could cause increased impedance resultin...</p> <p><a href="#">U.S. Food &amp; Drug Administration ↗</a></p>	<p><b>FDA</b> <b>CRITICAL</b> 2016-06-08</p> <p><b>HeartWare Ventricular Assist System Controller Product Usage: For use as a bridge-to-cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure. The HVAD is designed for in-hospital and out-of-hospital settings, including transportation via fix-wing aircraft or helicopter</b></p> <p>Heartware, Inc.</p> <p>Loose connector ports in controller body.</p> <p><a href="#">U.S. Food &amp; Drug Administration ↗</a></p>
<p><b>FDA</b> <b>CRITICAL</b> 2009-09-22</p> <p><b>Penumbra Neuron Delivery Catheter 070, percutaneous catheter, catalog numbers PND6F070I058, PND6F070956, PND6F070I058M, and PND6F070956M; manufactured by Penumbra, Inc., Alameda, CA. Indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature.</b></p> <p>Penumbra Inc.</p> <p>Failure-- product can kink or ovalize, which may result in difficulty in catheter advancement or delivery of other...</p> <p><a href="#">U.S. Food &amp; Drug Administration ↗</a></p>	<p><b>PUBMED</b> <b>HIGH</b> 2026-07-01</p> <p><b>Hyaluronic acid-engineered infection-responsive liposomes achieve biofilm penetration and synergistic photothermal-photodynamic antibacterial therapy.</b></p> <p>Cao S</p> <p>Hyaluronic acid-engineered infection-responsive liposomes achieve biofilm penetration and synergistic photothermal-...</p> <p><a href="#">PubMed (NCBI E-utilities) ↗</a></p>

SEC HIGH 2026-05-07

**ORGO — 8-K filing**

ORGO

8-K

---

SEC EDGAR ↗

SEC HIGH 2026-05-06

**MMM — 8-K filing**

MMM

8-K

---

SEC EDGAR ↗

SEC HIGH 2026-05-06

**KRMD — 8-K filing**

KRMD

FORM 8-K CURRENT REPORT FOR 05-06-2026

---

SEC EDGAR ↗

PUBMED HIGH 2026-05-06

**NIR-Enhanced Catalytic High Entropy Alloy Nanozyme Hydrogel for Synergistic Biofilm Elimination and Wound Regeneration.**

Wang X

NIR-Enhanced Catalytic High Entropy Alloy Nanozyme Hydrogel for Synergistic Biofilm Elimination and Wound...

---

PubMed (NCBI E-utilities) ↗

## Reimbursement watchlist

CMS LOCAL COVERAGE DETERMINATIONS · 2025-2026

### Live LCD rewrites on cellular and tissue-based products are reshaping coverage.

Multiple Medicare Administrative Contractors are revising LCDs for skin substitute grafts and cellular & tissue-based products (CTPs) used on chronic wounds. Coverage shifts here move billions in run-rate revenue across publicly traded wound-care issuers. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.

## Monitored issuers and operators


<p><b>Organogenesis</b>  <b>ORGO</b> Canton, MA</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Organogenesis</p>	<p><b>MiMedx</b>  <b>MDXG</b> Marietta, GA</p> <p><b>BIOTECH</b></p> <p>/atlas?company=MiMedx</p>	<p><b>Integra LifeSciences</b>  <b>IART</b> Princeton, NJ</p> <p><b>MEDTECH</b></p> <p>/atlas?company=Integra%20LifeSciences</p>
<p><b>Smith+Nephew</b>  <b>SNN</b> Watford, UK</p> <p><b>BIGPHARMA</b></p> <p>/atlas?company=Smith%2BNephew</p>	<p><b>ConvaTec</b>  <b>CNVA</b> Reading, UK</p> <p><b>MEDTECH</b></p> <p>/atlas?company=ConvaTec</p>	<p><b>Mölnlycke Health Care</b>  Gothenburg, SE</p> <p><b>MEDTECH</b></p> <p>/atlas?company=M%C3%B6lnlycke%20Health%20Care</p>
<p><b>Urgo Medical</b>  Chenôve, FR</p> <p><b>MEDTECH</b></p> <p>/atlas?company=Urgo%20Medical</p>	<p><b>Coloplast</b>  <b>COLO</b> Humlebæk, DK</p> <p><b>MEDTECH</b></p> <p>/atlas?company=Coloplast</p>	<p><b>3M Wound Care</b>  <b>MMM</b> Maplewood, MN</p> <p><b>BIGPHARMA</b></p> <p>/atlas?company=3M%20Wound%20Care</p>
<p><b>Hollister</b>  Libertyville, IL</p> <p><b>MEDTECH</b></p> <p>/atlas?company=Hollister</p>	<p><b>Tissue Regenix</b>  <b>TRX</b> Leeds, UK</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Tissue%20Regenix</p>	<p><b>Polynovo</b>  <b>PNV</b> Melbourne, AU</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Polynovo</p>
<p><b>Avita Medical</b>  <b>AVH</b> Valencia, CA</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Avita%20Medical</p>	<p><b>Kerecis</b>  Isafjordur, IS</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Kerecis</p>	<p><b>RenovaCare</b>  RoseLand, NJ</p> <p><b>EMERGING</b></p> <p>/atlas?company=RenovaCare</p>
<p><b>Reapplix</b>  Birkerød, DK</p> <p><b>EMERGING</b></p> <p>/atlas?company=Reapplix</p>	<p><b>PolarityTE</b>  Salt Lake City, UT</p> <p><b>EMERGING</b></p> <p>/atlas?company=PolarityTE</p>	<p><b>Anika Therapeutics</b>  <b>ANIK</b> Bedford, MA</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Anika%20Therapeutics</p>
<p><b>Vericel</b>  <b>VCEL</b> Cambridge, MA</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Vericel</p>	<p><b>Acera Surgical</b>  St. Louis, MO</p> <p><b>EMERGING</b></p> <p>/atlas?company=Acera%20Surgical</p>	<p><b>Aroa Biosurgery</b>  <b>ARX</b> Auckland, NZ</p> <p><b>BIOTECH</b></p> <p>/atlas?company=Aroa%20Biosurgery</p>
<p><b>Misonix (Bioventus)</b>  <b>BVS</b> Durham, NC</p> <p><b>MEDTECH</b></p>	<p><b>Convatec / Triad</b>  Brookfield, WI</p> <p><b>MEDTECH</b></p>	<p><b>Hartmann Group</b>  Heidenheim, DE</p> <p><b>MEDTECH</b></p> <p>/atlas?company=Hartmann%20Group</p>

<a href="/atlas?company=Misonix%20(Bioventus)">/atlas?company=Misonix%20(Bioventus)</a>	<a href="/atlas?company=Convatec%20%2F%20Triad">/atlas?company=Convatec%20%2F%20Triad</a>	
<b>BSN Medical (Essity)</b> Hamburg, DE MEDTECH <a href="/atlas?company=BSN%20Medical%20(Essity)">/atlas?company=BSN%20Medical%20(Essity)</a>	<b>Medline Industries</b> Northfield, IL MEDTECH <a href="/atlas?company=Medline%20Industries">/atlas?company=Medline%20Industries</a>	<b>Cardinal Health Wound</b> CAH Dublin, OH BIGPHARMA <a href="/atlas?company=Cardinal%20Health%20Wound">/atlas?company=Cardinal%20Health%20Wound</a>
<b>Acelity (KCI legacy → 3M)</b> MMM San Antonio, TX BIGPHARMA <a href="/atlas?company=Acelity%20(KCI%20Legacy%20%E2%86%92%203M)">/atlas?company=Acelity%20(KCI%20Legacy%20%E2%86%92%203M)</a>	<b>PiNon Medical</b> Plymouth, MN EMERGING <a href="/atlas?company=PiNon%20Medical">/atlas?company=PiNon%20Medical</a>	<b>Tissium</b> Paris, FR EMERGING <a href="/atlas?company=Tissium">/atlas?company=Tissium</a>

05 - 90-DAY SIGNAL TIMELINE

Hover any bar for week detail

## Volume & cadence of public disclosure



## Saudi Arabia · Vision 2030

KSA · LOWER-EXTREMITY AMPUTATION REDUCTION

### Diabetic foot disease is a Vision 2030 health priority — and the verification problem is national.

The Kingdom of Saudi Arabia carries one of the highest diabetes prevalence rates among adults globally, with diabetic foot ulcer progression to lower-extremity amputation a stated reduction target inside the Ministry of Health's Vision 2030 health-system transformation goals. Decisions of this scale — coverage policy, formulary, capital procurement of advanced wound therapies — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer.

AimwellBio is built for that layer. Every signal in this report carries its origin URL and fetch timestamp. Every claim is reproducible. Every gap is disclosed.

~18%

Adult diabetes prevalence, KSA

\$12–15B

Global advanced wound-care TAM

7

Public sources triangulated per signal class

#### METHODOLOGY

This report is generated from a live ingest pipeline ( `tools/scout-ingest` ). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated 07 May 2026 21:28:48Z. Every signal carries source URL and fetch timestamp; click any card to view origin.

**Confidence framework.** Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.

**Limitations.** This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA.